Garg Pushkal

ALNY EVP Chief R&D Pushkal Garg sells 4,713 shares ($1.5M) across 12 trades on Mar 4-5 at blended avg $323.53.

Pushkal Garg, EVP Chief R&D at Alnylam, executed 12 separate sales totaling 4,713 shares for $1,524,795.55 on March 4-5, 2026, reducing his holdings by 20.1% from 23,406 to 18,693 shares. The stock currently trades at $320.66, down 34.7% from its 52-week high and off 8.9% in the past 30 days, suggesting the sales occurred near a local high relative to recent momentum. Garg's cross-ticker track record shows a 90-day well-timed rate of 100.00% across 20 prior sells, indicating his historical sales have consistently preceded stock declines; however, his ALNY-specific prior trades (5 sells on March 2-3) remain too recent to measure outcome, so this ticker's pattern is not yet established. The multi-transaction structure and magnitude of the stake reduction merit monitoring for context around company fundamentals or forward guidance.

EVP Chief R&D Garg Pushkal sells 3,492 shares of ALNY for $1,130,131.45 in 14 transactions over two days.

Pushkal executed 14 separate sales totaling 3,492 shares for $1,130,131.45 ($1.1M) between March 2–3, 2026, reducing his stake by -13.0% to 23,406 shares post-transaction. The blended average price across the sales was $323.63, while the current stock price of $327.30 sits -33.4% below the 52-week high of $491.22 and the stock has declined -3.5% over the past 30 days and -29.7% over the past 90 days. His cross-ticker track record shows a 100.00% well-timed rate on 20 prior sells with an average 90-day return of -12.1%, though ALNY-specific outcomes remain limited and not yet measurable. This sale occurs in a company with strong fundamentals—annual revenue growth of +65.2%, net income of $251,084,000.00, and a market cap of $43,407,555,031.20—though the elevated P/E of 68.33 reflects market expectations that may not be fully aligned with near-term performance.

EVP Chief R&D Garg sells 4,627 shares for $1.5M (avg $331.34) as stock falls -30.1% over 90 days from high of $491.22

Pushkal Garg, EVP Chief R&D, executed 5 separate sales totaling 4,627 shares for $1,533,099.58 on 2026-02-27 at a blended average price of $331.34, reducing his holdings by 17.3% to 22,129 shares post-transaction. The stock has declined 30.1% over the past 90 days and trades 33.8% below its 52-week high of $491.22, though fundamentals remain strong with revenue growth of 65.2% and net income of $251,084,000.00 on the latest quarter. Garg's cross-ticker track record shows a 90-day well-timed sell rate of 100.00% across 20 prior sales, though his same-ticker history at ALNY (5 prior trades) has no measurable outcomes yet, limiting conclusions about his timing accuracy at this specific stock. The magnitude of this sale—$1.5M in proceeds—combined with the substantial recent price deterioration creates a data point worth monitoring against the company's strong operational performance.

EVP Chief R&D Garg sold 5,959 shares (22.8% of holdings) for $2.7M across 17 separate transactions on Oct 2–3.

Garg executed 17 separate sales totaling 5,959 shares for $2,692,061.89 over two consecutive trading days, reducing his position from 26,180 shares to 20,221 shares at blended average price $451.76. The transaction size (22.8% reduction in holdings) and multi-tranche execution pattern—with prices ranging from $446.53 to $457.64 and relatively tight clustering around $451–$453—are notable for a Chief R&D officer. His cross-ticker track record shows 20 prior sells with 0.00% well-timed rate at the 90-day horizon and an average 90-day return of +20.1%, indicating prior sales were followed by stock appreciation. At ALNY specifically, his five prior sales on 2025-08-19 showed negative 30-day returns (-0.7% to -2.1%), but 90-day outcomes remain unmeasurable. The company generated $773.7M in latest-quarter revenue with +23.0% annual growth but reported a net loss of $-66.3M and remains unprofitable on a full-year basis. Current price of $456.35 is -5.4% from the 52-week high and reflects a +2.0% 30-day appreciation.

EVP Chief R&D Garg sells 2,851 shares across 14 transactions for $1,299,745.87 (blended avg $455.89), reducing stake to 20,221 shares.

Pushkal Garg, EVP Chief R&D, executed 14 separate sales totaling 2,851 shares for $1,299,745.87 on 2025-08-18 and 2025-08-19, reducing his holdings by 12.4% from 23,072 to 20,221 shares. The stock currently trades at $458.28, at the 52-week high, having gained 43.0% over 30 days and 56.6% over 90 days. His prior five sales at ALNY have not been well-timed—none of the five prior trades showed a subsequent 90-day decline after the sale, meaning the stock rose in the periods following those sells. His cross-ticker track record across 20 prior sells shows a 0.00% well-timed rate with positive average 90-day returns of 21.3%, indicating his timing has historically favored the stock rising after his sales. Against a backdrop of strong recent price momentum and sustained unprofitability (net income $-66,277,000.00 in the latest quarter), the systematic scale of this sale—across multiple price points and two trading days—warrants observation of whether this marks a departure from the non-well-timed pattern established at this ticker.

CMO Garg sold 9,766 shares across 2 trades (Mar 21–24) for $2,864,985.00; reduced stake 32.6%.

Garg Pushkal, CMO & EVP Dev & Med Affairs, executed two separate sales on 2025-03-21 and 2025-03-24, totaling 9,766 shares for $2,864,985.00 at prices ranging from $285.00 to $300.00. This represents a 32.6% reduction in his holdings from 29,987 to 20,221 shares. The timing of these sales occurred at prices near the 52-week high ($300.55), with the stock currently trading at $280.96, suggesting the sales preceded a modest near-term pullback. Notably, Garg's prior five trades at ALNY (all on or around 2025-03-03 to 2025-03-04) remain unmeasured in outcome, and his cross-ticker track record across 20 prior sells shows a slight 90-day underperformance (-0.3% average return), indicating no strong pattern of prescient exit timing. The company remains unprofitable (annual net income negative) despite solid 23% annual revenue growth, which may be a relevant context for executive portfolio decisions.

CMO Garg sells 2,557 shares ($621.2K) at $242.92 avg across 14 transactions in 2 days

Pushkal Garg, CMO & EVP Dev & Med Affairs, executed 14 separate sales totaling 2,557 shares for $621,150.40 on March 3–4, 2025, reducing his stake by 9.4% from 27,099 to 24,542 shares. The sales occurred at prices ($242.37–$248.36) just below the current price of $249.23, suggesting modest underperformance relative to today's market but near his execution window. Garg's cross-ticker track record shows 100.00% well-timed rate on 20 prior sells (90-day outcomes negative, indicating he historically sold before declines), though those outcomes are measured across different securities and time horizons. At ALNY specifically, his 5 prior trades on 2025-02-18 remain unmeasurable (outcomes not yet available), so no ticker-specific pattern exists to contextualize this sale. The company posted $500.9M quarterly revenue (+23.0% annual growth) but remains unprofitable at $-111.6M net income, and the stock has declined 9.2% over 30 days and 1.0% over 90 days; the sale occurs in a period of modest downward pressure but without an identifiable catalyst or announcement co-filed with the Form 4.

CMO Garg sells 3,109 shares at $250–$265 range (avg $253.43); 20.6% of holdings in 18 transactions across 4 days.

Pushkal Garg, CMO & EVP Development & Medical Affairs, executed 18 separate sales totaling 3,109 shares for $787,904.15 across February 14–18, with transaction prices ranging from $250.11 to $264.87 and a blended average of $253.43. This represents a 20.6% reduction in his holdings, bringing his stake from 15,098 shares to 11,989 shares. His prior trades at ALNY show a 4 of 4 well-timed pattern at the 90-day mark (all prior sales preceded declines), though the outcome measurement window for his most recent sale on 2025-01-27 has not yet elapsed. The company reported $500.9M in latest quarterly revenue (+23.0% annual growth) but remains unprofitable with $-111.6M net income for the full fiscal year, setting the backdrop for this significant insider reduction.

CMO Garg Pushkal sold 52,592 shares of ALNY for $15.0M (81.4% of holdings); his prior 5 ALNY sales all showed negative 90-day returns.

Pushkal sold 52,592 shares at $285.00 on 2025-01-27, reducing his holdings from 64,581 to 11,989 shares. This is a material reduction (81.4% of pre-transaction holdings). His prior trade history at ALNY is distinctive: all 5 prior sales (clustered in August 2023) were followed by negative 90-day returns, ranging from -8.8% to -13.3%, indicating a 100% well-timed pattern at this ticker. His cross-ticker track record shows a 90-day well-timed rate of 90.00% with an average 90-day return of -6.0% after sales. The company remains unprofitable (net income $-111.6M in the latest quarter) despite strong revenue growth (+76.2% annually), creating a fundamental backdrop where insider selling historically preceded declines. The current price of $273.99 is -8.8% below the 52-week high of $300.55, though up 16.1% over 30 days, leaving the timing of this sale relative to near-term momentum uncertain.